The phrase "advanced candidates" is correct and usable in written English.
It can be used to refer to individuals who possess a high level of skill, knowledge, or experience in a particular field or subject, often in the context of job applications or educational programs.
Example: "The program is designed for advanced candidates who are looking to deepen their expertise in data science."
Alternatives: "experienced candidates" or "proficient candidates."
The volunteers for the plan were found simply by scouring the various training camps, either those offering basic training for foreigners arriving to fight with the Taliban or those for more advanced candidates who were being trained by al-Qaida instructors in techniques of urban terrorism.
The most advanced candidates are now in Phase 2 clinical trials and defining the therapeutic window, dosing schedule, and indication are the primary challenges for these potential first-in-class inhibitors.
Some of the clinically most advanced candidates are molecules with known MIC that were originally developed to treat other infectious diseases but have been repurposed for TB.
The current TB drug development pipeline also has extensive activity in the early stages (Zumla et al, 2013), but there is a gap, corresponding to late preclinical development and phase I clinical trials, that needs filling to ensure continuity of clinical activity and to compensate for the probable attrition among the more advanced candidates.
Of the current crop of about a dozen potential vaccines, the most advanced candidate didn't reach a large-scale clinical trial until 2009.
The new studies showed that the most advanced candidate vaccine — made by GlaxoSmithKline — cut illnesses in infants and young children by more than half and could safely be given with other childhood vaccines that are already routinely administered throughout Africa.
RTS,S is the most advanced candidate vaccine against human malaria.
The most clinically advanced candidate, RTS,S, is presently undergoing Phase 3 evaluation in young African children across 13 clinical sites in eight African countries.
The most advanced candidate vaccine for malaria lowers the risk of clinical episodes of malaria by only 31% among babies who receive their first dose between 6 and 12 weeks of age.
The most advanced candidate vaccine for malaria has cleared another major hurdle and is now ready for its last and biggest test: a phase III trial of 12,000 to 16,000 children at 11 locations in seven African countries.
Our most advanced candidate exhibits structural and bnAb binding properties comparable to full-length HA, completely protects mice in lethal heterologous and heterosubtypic challenge models, and reduces fever following sublethal challenge in cynomolgus monkeys.
